Teriparatide for Postsurgical Hypoparathyroidism

Stopped early · Phase 2

Conditions studied: Hypoparathyroidism Post-surgical

In brief

This study evaluated the effects of teriparatide (Forteo) on low calcium levels in the setting of thyroid surgery associated with low parathyroid hormone. The hypothesis was that teriparatide ( Forteo) would shorten the length of hospitalization post thyroidectomy in patients with symptomatic hypoparathyroidism.

Key facts

Study ID: NCT01171690
Run by: Mayo Clinic
People needed: 5
Starts: 2010-11-01
Expected to finish: 2013-12-01
Last updated by the study team: 2014-12-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients post bilateral thyroid bed surgery (cancer, Graves disease, multinodular goiter)
Symptomatic hypocalcemia
Total calcium < 8 mg/dL persisting after 24 hours of therapy with calcitriol (minimum 0.25 mcg twice a day) and calcium supplementation (minimum 1.5 grams of elemental calcium per day)
Parathyroid hormone (PTH) level below low end of normal range
Exclusion criteria (all subjects):
Renal failure
Any prior parathyroid pathology
Pre-existing hypercalcemia
Metabolic bone diseases other than osteoporosis
Pagets disease
Exclusion criteria (active treatment subjects only):
Ongoing therapy with Forteo for osteoporosis
Active non-thyroidal malignancy or suspicion of residual thyroid malignancy
History of skeletal malignancies, primary or metastatic
Pregnancy
Active or recent urolithiasis
Digitalis therapy
Patients at increased baseline risk for osteosarcoma, i.e., family history of osteosarcoma or prior radiation therapy involving the skeleton
Pediatric populations
Unexplained elevations of alkaline phosphatase

Where it is running

Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.